research use only
Cat.No.E4850
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT AMPK Histone Acetyltransferase |
|---|---|
| Other EZH2 Inhibitors | PF-06821497 GSK126 Tulmimetostat (CPI-0209) Valemetostat (DS-3201) GSK343 Lirametostat (CPI-1205) CPI-169 MS1943 SHR2554 EZH2/HSP90-IN-29 |
|
In vitro |
DMSO
: 100 mg/mL
(152.98 mM)
Ethanol : 3 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 653.65 | Formula | C34H44N4O4.BrH |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1467052-75-0 | Download SDF | Storage of Stock Solutions |
|
|
Read more about storage stability stock solution CAS number
| Targets/IC50/Ki |
EZH2
11 nM
EZH2
16 nM
EZH1
392 nM
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-04-02)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05994235 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma |
Weill Medical College of Cornell University |
2023-11-01 | PHASE2 |
| NCT06824701 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
University of Utah |
2025-09-12 | PHASE1 |
| NCT06068881 | WITHDRAWN | Follicular Lymphoma; Refractory Follicular Lymphoma |
Epizyme, Inc. |
2025-09-02 | PHASE2 |
| NCT06575686 | SUSPENDED | Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma |
City of Hope Medical Center |
2025-03-11 | PHASE2 |
| NCT05627232 | RECRUITING | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Thomas Jefferson University |
2023-08-28 | PHASE1 |
| NCT07407283 | RECRUITING | Prostate Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2026-04-08 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.